BeStock  
Stocks › Biotechnology › NAMS

NewAmsterdam Pharma NAMS

US equityMarket cap rank #2621Biotechnology
$18.41 −$1.10 (-5.64%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $18.32 -0.49%
Open$19.21
Prev close$19.51
Day range$18.29 – $19.78
Volume1.75M
Market cap$2.21B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$19.16M+5,406.9% YoY
Operating profit-$44.19M+19.9% YoY
Net profit-$17.39M+75.9% YoY
Diluted EPS-$0.14+77.0% YoY
Free cash flow-$39.95M-21.8% YoY
Operating cash flow-$39.77M

Revenue, last 8 quarters

$12.8MDec '24$3.0MMar '25$19.1MJun '25$348.0KSep '25$32.0KDec '25$3.0MMar '26$3.7MJun '26$19.2MSep '26

Net profit, last 8 quarters

$-92.2MDec '24$-39.5MMar '25$-17.4MJun '25$-72.0MSep '25$-74.9MDec '25$-48.4MMar '26$-64.1MJun '26$-17.4MSep '26

Diluted EPS by quarter

-0.95Dec '24-0.34Mar '25-0.15Jun '25-0.61Sep '25-0.63Dec '25-0.40Mar '26-0.52Jun '26-0.14Sep '26

Free cash flow by quarter

$-37.5MDec '24$-36.5MMar '25$-37.8MJun '25$-32.8MSep '25$-41.0MDec '25$-30.6MMar '26$-39.3MJun '26$-40.0MSep '26

Annual revenue

$0.0FY20$0.0FY21$102.7MFY22$14.1MFY23$45.6MFY24$22.5MFY25

Profitability & balance sheet

Operating margin-900.1%
Net margin-789.9%
Return on equity-30.2%
Return on assets-27.8%
Return on invested capital-32.7%
Current ratio11.76
Liabilities / assets8.3%
Cash & investments$628.24M
Total debt$49,000.00
Net cash (debt)$628.19M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $19.16M $3.70M $3.04M $22.50M $32,000.00
Total Operating Revenue $19.16M $3.70M $3.04M $22.50M $32,000.00
Operating Expense $63.35M $68.57M $61.46M $248.19M $66.01M
Selling and Admin Expenses $24.00M $26.89M $23.45M $106.35M $27.42M
Research & Development $39.36M $41.67M $38.01M $141.83M $38.59M
Operating Profit -$44.19M -$64.86M -$58.42M -$225.68M -$65.98M
Net Non-Operating Interest Income (Expense) $5.19M $5.81M $5.65M $27.59M $6.47M
Non-Operating Interest Income $5.19M $5.81M $5.65M $27.59M $6.47M
Other Income (Expense) $22.82M -$5.08M $4.33M -$5.73M -$15.42M
Gain on Sale of Security $22.82M -$5.08M $4.33M -$9.72M -$15.42M
Special Income (Charges) $0.00 $0.00 $0.00 $3.99M $0.00
-Less:Restructuring and Mergern & Acquisition $0.00 $0.00 $0.00 -$3.99M $0.00
Pretax Profit -$16.18M -$64.14M -$48.44M -$203.82M -$74.92M
Tax $1.21M $0.00 $0.00 $0.00 $0.00
Net Profit -$17.39M -$64.14M -$48.44M -$203.82M -$74.92M
Profit from Continuing Operations -$17.39M -$64.14M -$48.44M -$203.82M -$74.92M
Net Income to Parent Company -$17.39M -$64.14M -$48.44M -$203.82M -$74.92M
Net Income to Common Stockholders -$17.39M -$64.14M -$48.44M -$203.82M -$74.92M
Basic EPS -$0.14 -$0.52 -$0.40 -$1.72 -$0.63
Diluted EPS -$0.14 -$0.52 -$0.40 -$1.72 -$0.63
-General & Admin Expense – – – $106.35M $27.42M

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $687.99M $704.45M $732.64M $769.28M $769.28M
Total Current Assets $672.16M $659.21M $658.04M $675.70M $675.70M
Cash and Cash Equivalents & Short-Term Investments $628.24M $633.85M $636.11M $636.24M $636.24M
-Cash and Cash Equivalents $423.13M $424.15M $457.61M $490.00M $490.00M
-Short Term Investments $205.11M $209.70M $178.50M $146.24M $146.24M
Receivables $27.00M $5.35M $8.22M $23.15M $23.15M
-Taxes Receivable $303,000.00 $235,000.00 $206,000.00 $231,000.00 $231,000.00
-Other Receivables $26.69M $5.11M $8.02M $22.92M $22.92M
Prepaid Assets $15.43M $18.65M $12.38M $14.99M $14.99M
Restricted Cash $1.50M $1.36M $1.34M $1.32M $1.32M
Total Non-Current Assets $15.82M $45.25M $74.60M $93.58M $93.58M
Net PPE $629,000.00 $493,000.00 $400,000.00 $568,000.00 $568,000.00
-Gross PPE $629,000.00 $493,000.00 $400,000.00 $568,000.00 $568,000.00
Investments and Advances $14.88M $44.41M $71.24M $92.61M $92.61M
-Available for Sale Securities $14.88M $44.41M $71.24M $92.61M $92.61M
Goodwill and Other Intangible Assets $312,000.00 $343,000.00 $375,000.00 $407,000.00 $407,000.00
Total Liabilities $57.20M $73.03M $67.42M $85.85M $85.85M
Total Current Liabilities $57.15M $72.97M $67.42M $85.79M $85.79M
Payables $4.63M $5.42M $8.09M $8.97M $8.97M
-Accounts Payable $4.63M $5.42M $8.09M $8.97M $8.97M
Current Accrued Expenses $7.94M $4.71M $2.82M $6.07M $6.07M
Short-Term Debt and Capital Lease Obligation $27,000.00 $26,000.00 $23,000.00 $136,000.00 $136,000.00
-Current Capital Lease Obligation $27,000.00 $26,000.00 $23,000.00 $136,000.00 $136,000.00
Current Deferred Liabilities $5.71M $2.80M $3.99M $3.99M $3.99M
Other Current Liabilities $31.33M $54.45M $50.23M $57.27M $57.27M
Total Non-Current Liabilities $49,000.00 $56,000.00 $0.00 $66,000.00 $66,000.00
Long Term Debt and Capital Lease Obligation $49,000.00 $56,000.00 $0.00 $66,000.00 $66,000.00
-Long Term Capital Lease Obligation $49,000.00 $56,000.00 $0.00 $66,000.00 $66,000.00
Total Equity $630.78M $631.42M $665.22M $683.43M $683.43M
Stockholders' Equity $630.78M $631.42M $665.22M $683.43M $683.43M
Capital Stock $15.03M $14.74M $14.59M $14.28M $14.28M
-Common Stock $15.03M $14.74M $14.59M $14.28M $14.28M
Additional Paid-In Capital $1.50B $1.49B $1.46B $1.43B $1.43B
Retained Earnings -$892.36M -$874.97M -$810.83M -$762.39M -$762.39M
Gains/Losses Not Affecting Retained Earnings $3.62M $3.86M $4.22M $4.79M $4.79M
Non-Current Prepaid Assets – – $2.59M – –

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$39.77M -$39.21M -$30.60M -$147.78M -$40.88M
Net cash flow from continuing operations -$39.77M -$39.21M -$30.60M -$147.78M -$40.88M
Net Income from Continuing Operations -$17.39M -$64.14M -$48.44M -$203.82M -$74.92M
Gain/Loss from Continuing Operations -$22.82M $5.09M -$4.32M $5.74M $15.43M
Depreciation & Depletion & Amortization $67,000.00 $59,000.00 $62,000.00 $220,000.00 $59,000.00
Other Non-Cash Items $2,000.00 $3,000.00 -$16,000.00 – –
Change in Working Capital -$12.15M $1.44M $4.10M -$7.94M $4.57M
-Change in Prepaid Assets -$19.41M $135,000.00 $15.22M -$13.28M -$10.06M
-Change in Payables and Accrued Expense $4.35M $2.50M -$11.12M $7.36M $10.64M
-Change In Other Working Capital $2.91M – – -$2.02M $3.99M
Net cash flow from investing $33.70M -$4.76M -$11.51M -$174.92M -$21.14M
Net Cash Flow from Continuing Investing Activities $33.70M -$4.76M -$11.51M -$174.92M -$21.14M
Net PPE Purchase and Sale -$177,000.00 -$80,000.00 -$38,000.00 -$246,000.00 -$100,000.00
Net Investment Purchase and Sale $33.88M -$4.68M -$11.47M -$174.67M -$21.04M
Financing Cash Flow $5.45M $11.04M $11.07M $29.52M $13.68M
Net Cash Flow from Continuing Financing Activities $5.45M $11.04M $11.07M $29.52M $13.68M
Proceeds from Stock Option Exercised $5.45M $11.04M $11.07M $31.11M $13.68M
Ending Cash Balance $424.63M $425.51M $458.94M $491.32M $491.32M
Net Change in Cash -$623,000.00 -$32.94M -$31.05M -$293.18M -$48.33M
Beginning Cash Balance $425.51M $458.94M $491.32M $771.74M $539.72M
Effect of Exchange Rate Changes -$260,000.00 -$500,000.00 -$1.33M $12.76M -$60,000.00
Free Cash Flow -$39.95M -$39.29M -$30.64M -$148.03M -$40.98M
Net Common Stock Issuance – – – $0.00 $0.00
Net Other Financing Charges – – – -$1.59M $0.00

Discussion

No comments yet — be the first to weigh in on NAMS.

Sign in to join the discussion.

Scroll to Top